EnVVeno Medical Corporation (NASDAQ:NVNO) | Finanzwire

Basculer en Français

8235	Companies
111180	Keywords
52889	Articles
61026	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 03/06/2024 at 14:45, 8 months 4 days ago

EnVVeno Medical Corporation Announces Positive Results from VenoValve Pivotal Trial

FDA Approval EnVVeno Medical VenoValve Chronic Venous Insufficiency Clinical Improvement
PRESS RELEASE

published on 03/06/2024 at 14:40, 8 months 4 days ago

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
enVVeno Medical presents positive topline efficacy data from the SAVVE U.S. pivotal trial for the VenoValve at the 2024 American Venous Forum Annual Meeting, showing significant clinical improvement in CVI patients

EnVVeno Medical VenoValve Clinical Improvement SAVVE Trial CVI Patients
BRIEF

published on 02/29/2024 at 22:20, 8 months 10 days ago

EnVVeno Medical Reports Positive 2023 Financials and Clinical Progress

Medical Devices Clinical Trials Financial Results 2023 EnVVeno Medical VenoValve
PRESS RELEASE

published on 02/29/2024 at 22:15, 8 months 10 days ago

enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reports $46.4 million in cash, progress towards the VenoValve U.S. pivotal trial, and financial results for 2023, anticipating value driving milestones in 2024

Financial Results Clinical Trials VenoValve EnVVeno Medical Corporation Value Driving Milestones
PRESS RELEASE

published on 02/20/2024 at 14:30, 8 months 19 days ago

Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
enVVeno Medical to present topline efficacy data from VenoValve U.S. pivotal trial at 2024 AVF Annual Meeting. VenoValve aims to address severe Chronic Venous Insufficiency with innovative bioprosthetic solutions

Clinical Trial EnVVeno Medical VenoValve Chronic Venous Insufficiency AVF Annual Meeting
BRIEF

published on 02/20/2024 at 14:30, 8 months 19 days ago

Promising Results for enVVeno Medical in the Treatment of Venous Insufficiency

EnVVeno Medical VenoValve RVCSS Chronic Venous Insufficiency Venous Treatment
PRESS RELEASE

published on 12/14/2023 at 17:30, 10 months 27 days ago

enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
PRESS RELEASE

published on 11/16/2023 at 14:45, 11 months 24 days ago

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
PRESS RELEASE

published on 10/26/2023 at 14:05, 1 year ago

enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
PRESS RELEASE

published on 10/12/2023 at 15:00, 1 year ago

enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference

Accesswire

Published on 11/10/2024 at 02:00, 20 hours 26 minutes ago

Spey Resources Corp. enters into Share Exchange Agreement with Antimony Assets and announces Name Change
Published on 11/09/2024 at 16:30, 1 day 5 hours ago

New to the Street Premieres Episode 611 on Bloomberg Television Tonight at 6:30 PM EST, Featuring Zapp Electric Vehicles, OriginClea and PillSafe
Published on 11/09/2024 at 04:00, 1 day 18 hours ago

Freedom Holding Corp. Reports Second Quarter Fiscal Year 2025 Financial Results
Published on 11/08/2024 at 23:05, 1 day 23 hours ago

Murchison Minerals Announces Non-Brokered Private Placement
Published on 11/08/2024 at 22:30, 1 day 23 hours ago

Justera Health Announces RSU Grant

View all ACCESSWIRE

EQS Group

Published on 11/10/2024 at 13:20, 9 hours 5 minutes ago

EQS-Adhoc: Delivery Hero SE decides on the intended IPO of Talabat Holding plc and plans to use proceeds for general corporate purposes and capital structure optimisation
Published on 11/08/2024 at 18:35, 2 days 3 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/08/2024 at 18:20, 2 days 4 hours ago

ENCAVIS achieves results in the first three quarters of 2024 below the figures for the same period of the previous year due to unforeseeable events and adjusts guidance for the current financial year
Published on 11/08/2024 at 18:15, 2 days 4 hours ago

EQS-Adhoc: ENCAVIS AG
Published on 11/08/2024 at 18:02, 2 days 4 hours ago

Funding Circle Plc: POS-Transaction in Own Shares

Les Echos

Published on 11/08/2024 at 18:00, 2 days 4 hours ago

Covivio - Information on total number of voting rights and share capital
Published on 11/08/2024 at 17:52, 2 days 4 hours ago

Total number of voting rights and shares making up the share capital at October 31, 2024
Published on 11/08/2024 at 17:45, 2 days 4 hours ago

CHARGEURS - Voting rights monthly statement as of October 31st, 2024
Published on 11/08/2024 at 17:35, 2 days 4 hours ago

Disclosure of the number of shares and the total number of voting rights as of October 31, 2024
Published on 11/08/2024 at 12:32, 2 days 9 hours ago

Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)

View all LES ECHOS COMFI WIRE